

**NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE
OR DISSEMINATION IN THE UNITED STATES**



3-305 Industrial Parkway South
Aurora, Ontario, Canada, L4G 6X7
Phone: (905) 841-2300
Fax: (905) 841-2244
Web: www.helixbiopharma.com

**May 14, 2015
NEWS RELEASE**

HELIX BIOPHARMA CORP. announces the publication of a peer-reviewed L-DOS47 paper in The Journal of Bioconjugate Chemistry

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the publication of a peer-reviewed L-DOS47 manuscript in “*The Journal of Bioconjugate Chemistry*”.

The article, entitled “Production and Characterization of a Camelid Single Domain Antibody–Urease Enzyme Conjugate for the Treatment of Cancer”, describes the efficacy of L-DOS47 in CEACAM6 positive cancer cell lines and in a human xenograft animal model. The article also explains, in detail, the construction and characterization of the L-DOS47 molecule.

L-DOS47 is Helix's first immunoconjugate-based drug candidate in development based upon Helix's novel DOS47 technology, which is designed to use an innovative approach to modify the microenvironmental conditions of cancer cells in a manner that leads to their destruction. L-DOS47 is currently being clinically evaluated in both the United States and Poland as a potential treatment for patients with NSCLC.

The article is available in the “As Soon As Publishable” section of the Journal’s website and it adds to the body of scientific information on L-DOS47. A copy of the article can also be found on Helix’s website.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol “HBP”.

Investor Relations:

Helix BioPharma Corp.

Tel: 905 841-2300

Email: ir@helixbiopharma.com

This press release is not an offer of securities for sale in the United States. Helix's common shares have not been registered under the *Securities Act of 1933*, as amended, and may not be offered or sold in the United States absent an exemption from registration thereunder.

Forward-Looking Information and Risks and Uncertainties

This news release contains certain forward-looking statements and information (collectively, "forward-looking information") within the meaning of applicable Canadian securities laws. Forward-looking information means disclosure regarding possible events, conditions or other matters that is based on assumptions about future economic conditions and courses of action and includes statements regarding plans, goals, objectives, intentions and expectations with respect to Helix's future business, operations, research and development, including Helix's activities relating to L-DOS47 and other information in future periods. Forward-looking information may be identified by words including, without limitation, "potential" and other similar expressions, which are intended to provide information about management's current plans and expectations regarding the conduct of the clinical studies of L-DOS47 and the other operations of Helix.

Although Helix believes that the expectations reflected in such forward-looking information are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation the inherent uncertainty involved in scientific research and drug development and those risks and uncertainties affecting Helix as more fully described in Helix's most recent Annual Information Form, including under the headings "Forward-Looking Statements" and "Risk Factors", filed under Helix's profile on SEDAR at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors or assumptions are applied in making the forward-looking information, including, without limitation, that the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking information.

Forward-looking information is based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.
